Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Transitional Cell Carcinoma of the Bladder: early-phase trial registry
A small indexed set (5 trials) with no open enrollment listed right now.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · none currently recruiting · #3,391 of 28,707 conditions by registered trial count
Transitional Cell Carcinoma of the Bladder: 5 US clinical trials tracked, none currently recruiting.
Transitional Cell Carcinoma of the Bladder is the subject of 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition transitional-cell-carcinoma-of-the-bladder
OPEN 0 | RECR 0% | LATE 0 | EARLY 5 | RANK #3391 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Transitional Cell Carcinoma of the Bladder has no open enrollment in this registry pull (5 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Transitional Cell Carcinoma of the Bladder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Transitional Cell Carcinoma of the Bladder is recruiting below its size-band peers.
0 of 5 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Transitional Cell Carcinoma of the Bladder research.
National Cancer Institute (NCI) accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Transitional Cell Carcinoma of the Bladder trials plan to enrol fewer than 100 people.
Median target enrolment is 24 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.
-
Transitional Cell Carcinoma of the Bladder research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Five Prime Therapeutics
NCT02318329
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
National Cancer Institute (NCI)
NCT00072150
Gene Therapy in Treating Patients With Advanced Bladder Cancer
National Cancer Institute (NCI)
NCT00003167
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
National Cancer Institute (NCI)
NCT00471536
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology
NCT03081858
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Transitional Cell Carcinoma of the Bladder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Transitional Cell Carcinoma of the Bladder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Transitional Cell Carcinoma of the Bladder page
5 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Transitional Cell Carcinoma of the Bladder trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Transitional Cell Carcinoma of the Bladder trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Transitional Cell Carcinoma of the Bladder condition card totals 5 registered trials; most-linked intervention TSD-001; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.